Disease relevance of NORTRON

• Editorial: Progress in the treatment of colorectal cancer [1].
• Oral contraceptives and breast cancer. Progress report of an epidemiological study [2].
• PURPOSE: Progress has been made in the treatment of medulloblastoma, the most common childhood malignant brain tumor: However, many long-term survivors will have posttherapy growth hormone insufficiency with resultant linear growth retardation [3].
• METHODS: Articles describing randomized, placebo-controlled trials of cyclobenzaprine in people with fibromyalgia were obtained from Medline, EMBase, Psyclit, the Cochrane Library, and Federal Research in Progress Database. Unpublished literature and bibliographies were also reviewed [4].
• Detection of Epstein-Barr virus by in situ hybridization. Progress toward development of a nonisotopic diagnostic test [5].

Psychiatry related information on NORTRON

• Alzheimer's disease. Progress in molecular pathology [6].
• Reform of mental health care in Europe. Progress and change in the last decade [7].
• Taken together, they support the contention of Lavond [Annu Rev Psychol 1993;44:317-42], Thompson [In: Sprague JM, Epstein AN, editors. Progress in Psychobiology and Physiological Psychology. New York: Academic Press 1983, pp. 167-96], Yeo et al [8].
• Reductions of pain were assessed by changes in the Visual Analog Scale; physical activities, attitude, and medication intake were graded by the Pain Progress Score recorded before each treatment and 2 wk after the last [9].
• Predator exposure produces retrograde amnesia and blocks synaptic plasticity. Progress toward understanding how the hippocampus is affected by stress [10].

High impact information on NORTRON

• EC biotechnology policy. Progress on animal patents [11].
• Cancer chemotherapy. Progress in understanding multidrug resistance [12].
• Retinitis pigmentosa. Progress in sight [13].
• Genome research. Progress for the 'mouse gene encyclopedia' [14].
• Proceedings of the meeting will be published in Progress in Brain Research in 2005 [15].

Chemical compound and disease context of NORTRON

• Averting iatrogenic hypoglycemia through glucose prediction in clinical practice: Progress towards a new procedure in diabetes [16].

Biological context of NORTRON

• This volume of Progress in Biophysics and Molecular Biology incorporates clinical and basic science results, and it is fitting that its publication coincides with a special session on cardiac MEF at the 2003 meeting of NASPE [17].
• ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise [18].
• Time for plants. Progress in plant chronobiology [19].
• The LOXN2 gene was tightly conserved in the Progress 9 and MG103738 genotypes, respectively, susceptible and resistant to the root cyst nematode Heterodera goettingiana [20].
• Diuretic drugs. Progress in clinical pharmacology [21].

Anatomical context of NORTRON

• Human visual cortex. Progress and puzzles [22].
• Non-VR-trained residents were nine times more likely to transiently fail to make progress (P <.007, Mann-Whitney test) and five times more likely to injure the gallbladder or burn nontarget tissue (chi-square = 4.27, P <.04) [23].
• The F:V data were analyzed within the framework of the Huxley model (Huxley. 1957. Progress in Biophysics and Biophysical Chemistry. 7:255-318) for contraction and interpreted to indicate that in smooth muscle, as compared with fast striated muscle, there may exist a greater percentage of attached force-generating cross-bridges [24].
• Clinical review 133: Progress in understanding the etiology of thyroid autonomy [25].
• (4) We review how integrated viral attack of the host immune system also targets DCs: Progress in understanding the immunobiology of MV-infected DCs that could account for MV-induced immunosuppression observed in vivo is presented and their potential role in lymphopenia is underlined [26].

Associations of NORTRON with other chemical compounds

• Two classes of NOS-expressing neurons, type I and type II, had already been distinguished in the INL [Koistinaho, J. & Sagar, S.M. (1995) In Osborne, N.N. & Chader, G.J. (eds), Progress in Retinal and Eye Research, Vol. 15. Oxford University Press, pp. 69-87] and a third one in the GCL [27].
• Apigenin and cancer chemoprevention: Progress, potential and promise (Review) [28].
• Organization of the pathway of de novo pyrimidine nucleotide biosynthesis in pea (Pisum sativum L. cv Progress No. 9) leaves [29].
• Triadimefon, a fungicide, and ethofumesate, an herbicide, are commonly applied to turfgrass in the Pacific Northwest, resulting in foliar residues [30].
• Chlorpropham affected growth only in Agrostemma, while ethofumesate reduced growth in one third of the higher plant species [31].

Gene context of NORTRON

• Design, Synthesis, and Progress toward Optimization of Potent Small Molecule Antagonists of CC Chemokine Receptor 8 (CCR8) [32].
• The Prostate Cancer Progress Report to the Director of NCI in 1998 challenged the research community to design more efficient CP trials for prostate cancer [33].
• By log-rank analysis, an MIB-1 LI of more than 2.0 was associated with shortened PFS (P =.035) [34].
• BACKGROUND: Progress in the diagnosis, localization of abnormal parathyroids, and intraoperative management of primary hyperparathyroidism has been observed over the past 34 years [35].
• BACKGROUND: Progress in molecular genetics has led to the identification of point mutations in the transthyretin (TTR) gene in FAP--a dominantly inherited neuropathy with a fatal outcome [36].

Analytical, diagnostic and therapeutic context of NORTRON

• Positron emission tomography. Progress in brain imaging [37].
• We also searched EMBASE, HealthStar (Health Services, Technology, Administration, and Research), and HSRPROJ (Health Services Research Projects in Progress) via Internet Grateful Med and The Cochrane Library and hand searched abstract proceedings from intensive care national scientific meetings (January 1, 1994, through December 31, 2001) [38].
• METHODS: We searched the MEDLINE (1966-2000), PsycLit, Cinhal, EMBASE, AIDSLINE, HealthSTAR, CANCERLIT, the Cochrane Library (clinical trials registry and the Database of Systematic Reviews), Micromedex, and Federal Research in Progress databases and references of reviewed articles [39].
• CONCLUSIONS: Progress during the past 15 years has enabled us to perform pediatric liver transplantation with near perfect patient survival [40].
• Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s [41].

References